FOXO4-DRI Peptide Reverses Cellular Aging Markers in Preclinical Study

Cellular senescence, where cells stop dividing but remain metabolically active and secrete inflammatory factors, is a key driver of aging and age-related diseases like metabolic dysfunction and frailty. Accumulation of these "zombie cells" contributes to tissue damage and chronic inflammation. While senolytics (compounds that selectively eliminate senescent cells) show promise, the precise mechanisms and efficacy of targeted FOXO4 inhibition in vivo remain underexplored.

Treatment with FOXO4-DRI significantly reduced senescent cell markers and improved physiological function across multiple parameters. The high-dose FOXO4-DRI group showed a 48% reduction in p16INK4a expression and a 35% reduction in SA-β-gal positive cells (a marker for senescent cells) in liver and kidney tissues compared to controls (p<0.001). Physical performance metrics also saw substantial gains: grip strength increased by 27% (p<0.01) and treadmill endurance improved by 32% (p<0.01) in the high-dose group. Furthermore, fasting glucose levels were reduced by 18% (p<0.05), and glucose tolerance improved by 2.1-fold compared to the saline group. The lower dose group showed milder, but statistically significant, improvements. The high-dose FOXO4-DRI treatment led to a 48% reduction in key senescent cell markers, demonstrating potent senolytic activity and significant reversal of age-related cellular burden.